| scholarly article | Q13442814 |
| P2093 | author name string | P. Muus | |
| S. T A. Van Bijnen | |||
| W. L. Van Heerde | |||
| P2860 | cites work | Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories | Q81411565 |
| Antiphospholipid antibodies in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab | Q83764453 | ||
| Thrombosis in Paroxysmal Nocturnal Hemoglobinuria - insights into the role of complement in thrombosis | Q84140432 | ||
| A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab | Q84309496 | ||
| Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria | Q84461680 | ||
| Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism | Q84737551 | ||
| The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes | Q84773086 | ||
| Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) | Q127085727 | ||
| Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry. | Q127154815 | ||
| How I treat paroxysmal nocturnal hemoglobinuria | Q24648538 | ||
| Diagnosis and management of paroxysmal nocturnal hemoglobinuria | Q24670119 | ||
| Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation. | Q30990142 | ||
| Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient | Q33334463 | ||
| Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria | Q33340065 | ||
| Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria | Q33377654 | ||
| Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology | Q33496713 | ||
| Vascular-bed--specific hemostasis and hypercoagulable states | Q33637363 | ||
| Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab | Q33800427 | ||
| Clinical guidelines for testing for heritable thrombophilia | Q34096556 | ||
| Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). | Q34219091 | ||
| Natural history of paroxysmal nocturnal hemoglobinuria | Q34296074 | ||
| Membrane microparticles: two sides of the coin | Q34384910 | ||
| The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease | Q34409133 | ||
| Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria | Q34429673 | ||
| Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo | Q34554891 | ||
| Microparticles in hemostasis and thrombosis. | Q35131040 | ||
| Active tissue factor pathway inhibitor is expressed on the surface of coated platelets | Q35642785 | ||
| Endothelial progenitor cells for vasculogenesis | Q36011396 | ||
| Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients | Q36158746 | ||
| The response of human platelets to activated components of the complement system | Q36845198 | ||
| Vascular bed-specific thrombosis | Q36884433 | ||
| Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site | Q37317725 | ||
| Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. | Q37438142 | ||
| Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator | Q37561638 | ||
| Management of paroxysmal nocturnal haemoglobinuria: a personal view. | Q37868639 | ||
| A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression | Q40281254 | ||
| Induction of cellular procoagulant activity by the membrane attack complex of complement | Q40946237 | ||
| The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria | Q40993621 | ||
| NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils | Q41792377 | ||
| The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity | Q41923727 | ||
| Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3. | Q42748319 | ||
| Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria | Q42783308 | ||
| Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria | Q43129386 | ||
| Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria | Q44755395 | ||
| The platelet function defect of paroxysmal nocturnal haemoglobinuria | Q44941578 | ||
| Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview | Q45119487 | ||
| Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor | Q46571946 | ||
| Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size | Q47441031 | ||
| Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan | Q47670449 | ||
| Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria | Q50548486 | ||
| Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria | Q50568895 | ||
| Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria | Q50648020 | ||
| Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor | Q51835800 | ||
| Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival | Q52845900 | ||
| Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria | Q52853130 | ||
| Circulating procoagulant microparticles in cancer patients | Q53292843 | ||
| Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases | Q53425303 | ||
| Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes | Q53509755 | ||
| Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency | Q55671185 | ||
| Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis | Q56995556 | ||
| Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase | Q57779720 | ||
| Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study | Q58034420 | ||
| Circulating tissue factor and microparticles are not increased in patients with deep vein thrombosis | Q59161677 | ||
| Repopulation of liver endothelium by bone-marrow-derived cells | Q60998173 | ||
| Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study | Q63953568 | ||
| Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases | Q68374613 | ||
| Activated platelets in paroxysmal nocturnal haemoglobinuria | Q70883338 | ||
| Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets | Q71127533 | ||
| Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria | Q71713168 | ||
| Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils | Q73119877 | ||
| Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity | Q73256348 | ||
| Paroxysmal nocturnal hemoglobinuria with no evidence of hemolysis presenting as Budd-Chiari syndrome | Q73533403 | ||
| Complement-induced procoagulant alteration of red blood cell membranes with microvesicle formation in paroxysmal nocturnal haemoglobinuria (PNH): implication for thrombogenesis in PNH | Q78116302 | ||
| Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells | Q79804242 | ||
| Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria | Q80166801 | ||
| Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays | Q80203889 | ||
| Lysis and thrombosis: manifestation of the same disease | Q80623657 | ||
| High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria | Q81225766 | ||
| Stroke in paroxysmal nocturnal haemoglobinuria: patterns of disease and outcome | Q81235631 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 1-10 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria | |
| P478 | volume | 10 |
| Q64227043 | Abdominal Surgical Emergencies in Patients with Hematological Disorders: An Exacting Experience for Surgeons |
| Q92637350 | Acute myocardial infarction in a Chinese patient with paroxysmal nocturnal hemoglobinuria: A case report |
| Q90014642 | Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China |
| Q90029392 | Anticoagulating patients with high-risk acquired thrombophilias |
| Q40064380 | Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report |
| Q92504737 | Bilateral Multiple Focal Choroidal Excavations in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Q64065190 | Differential miRNA expression profile and proteome in plasma exosomes from patients with paroxysmal nocturnal hemoglobinuria |
| Q24193045 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q24201126 | Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria |
| Q48078070 | Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria |
| Q91790122 | Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls - A Critical Review Article |
| Q41980631 | Idiopathic thrombosis of the inferior vena cava and bilateral femoral veins in an otherwise healthy male soldier |
| Q33408378 | Isolated central retinal artery occlusion as an initial presentation of paroxysmal nocturnal hemoglobinuria and successful long-term prevention of systemic thrombosis with eculizumab |
| Q90484775 | Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry |
| Q37638781 | Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide |
| Q41430132 | Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab |
| Q42821159 | Paroxysmal nocturnal hemoglobinuria presenting as cerebral venous sinus thrombosis: a case report |
| Q46683290 | Polymorphism of the ABO gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria |
| Q37055675 | Positive predictive value of diagnosis coding for hemolytic anemias in the Danish National Patient Register. |
| Q83528363 | Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab |
| Q91655288 | Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles |
| Q48925994 | Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria. |
| Q33407861 | Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells |
| Q37638779 | Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease |
| Q41693572 | Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis |
| Q27021748 | The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review |
| Q42348709 | Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated? |
| Q35825548 | Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. |
Search more.